SERPINA4 Antibody (C-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P29622 |
---|---|
Clone Names | 80917066 |
Gene ID | 5267 |
---|---|
Other Names | Kallistatin, Kallikrein inhibitor, Peptidase inhibitor 4, PI-4, Serpin A4, SERPINA4, KST, PI4 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP7455b was selected from the C-term region of human SERPINA4. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | SERPINA4 |
---|---|
Synonyms | KST, PI4 |
Function | Inhibits human amidolytic and kininogenase activities of tissue kallikrein. Inhibition is achieved by formation of an equimolar, heat- and SDS-stable complex between the inhibitor and the enzyme, and generation of a small C-terminal fragment of the inhibitor due to cleavage at the reactive site by tissue kallikrein. |
Cellular Location | Secreted. |
Tissue Location | Expressed by the liver and secreted in plasma. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
SERPINA4 inhibits human amidolytic and kininogenase activities of tissue kallikrein. The inhibition is achieved by formation of an equimolar, heat- and SDS-stable complex between the inhibitor and the enzyme, and generation of a small C-terminal fragment of the inhibitor due to cleavage at the reactive site by tissue kallikrein.
References
Chai K.X., Chen L.-M.J. Biol. Chem. 268:24498-24505(1993)Chai K.X., Ward D.C.Genomics 23:370-378(1994)Zhou G.X., Chao L.J. Biol. Chem. 267:25873-25880(1992)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.